Subvisible Particles in Solutions of Remicade in Intravenous Saline Activate Immune System Pathways in In Vitro Human Cell Systems

Among patients that receive Remicade® therapy, more than 20% have adverse infusion related reactions and approximately 50% have immunogenic responses.1Radstake T.R. Svenson M. Eijsbouts A.M. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.Ann Rheum Dis. 2009; 68: 1739-1745Crossref PubMed Scopus (309) Google Scholar, 2Krintel S.B. Grunert V.P....